N-FMOC-piperidine-3-carbonyl chloride | 942272-46-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: N-FMOC-piperidine-3-carbonyl chloride
• 英文别名: (R)-(9H-fluoren-9-yl)methyl 3-(chlorocarbonyl)piperidine-1-carboxylate；9H-fluoren-9-ylmethyl 3-carbonochloridoylpiperidine-1-carboxylate
• CAS: 942272-46-0
• 化学式: C₂₁H₂₀ClNO₃
• 分子量: 369.848
• InChiKey: OAILBATVAQKSMI-UHFFFAOYSA-N

物化性质

• 沸点：
  518.6±43.0 °C(Predicted)
• 密度：
  1.294±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-FMOC-piperidine-3-carbonyl chloride 在 碳酸氢钠 、 4-氨甲基哌啶 作用下， 以 氯仿 为溶剂， 反应 13.0h， 生成 N-(6-甲基吡啶-2-基)哌啶-3-甲酰胺
  参考文献：
  名称：

  Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists

  摘要：

  A series of diaryl amides was designed and synthesized as novel nonethynyl mGluR5 antagonists. The systematic variation of the pharmacophoric groups led to the identification of a lead compound that demonstrated micromolar affinity for the mGluR5. Further optimization resulted in compounds with improved binding affinities and antagonist profiles, in vitro. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.04.032
• 作为产物：
  描述：

  (±)-N-Fmoc-3-哌啶甲酸 Fmoc-DL-哌啶甲酸 在 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 N-FMOC-piperidine-3-carbonyl chloride
  参考文献：
  名称：

  Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists

  摘要：

  A series of diaryl amides was designed and synthesized as novel nonethynyl mGluR5 antagonists. The systematic variation of the pharmacophoric groups led to the identification of a lead compound that demonstrated micromolar affinity for the mGluR5. Further optimization resulted in compounds with improved binding affinities and antagonist profiles, in vitro. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.04.032

文献信息

• Novel Tricyclic Compounds
  申请人：Wishart Neil

  公开号：US20090312338A1

  公开（公告）日：2009-12-17

  The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

  这项发明提供了一个符合Formula (I)的化合物，其中包括药用盐、前药、生物活性代谢物、立体异构体和同分异构体，其中变量在此处定义。该发明的化合物对治疗免疫和肿瘤疾病有用。
• SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS
  申请人：BANDIERA Tiziano

  公开号：US20110288088A1

  公开（公告）日：2011-11-24

  Substituted pyrrolo-pyrazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with dysregulated protein kinase activity, like cancer.

  本发明披露了公式(I)及其药学上可接受的盐的取代吡咯-吡唑衍生物，以及制备它们的过程和包含它们的制药组合物；本发明的化合物可能在治疗与蛋白激酶活性失调相关的疾病，如癌症中有用。
• NOVEL TRICYCLIC COMPOUNDS
  申请人：AbbVie Inc.

  公开号：US20150210708A1

  公开（公告）日：2015-07-30

  The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

  本发明提供了公式(I)的化合物，其包括药物可接受的盐、前药、生物活性代谢物、立体异构体和同分异构体，其中变量在此定义。本发明的化合物可用于治疗免疫和肿瘤疾病。
• TRICYCLIC KINASE INHIBITORS
  申请人：AbbVie Inc.

  公开号：EP3031324A2

  公开（公告）日：2016-06-15

  The invention provides a compound of Formula (Ie), pharmaceutically acceptable salts, prodrugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

  本发明提供了式(Ie)化合物、药学上可接受的盐、原药、生物活性代谢物、立体异构体和异构体，其中变量在本文中定义。本发明的化合物可用于治疗免疫学和肿瘤学疾病。
• WO2007/68637
  申请人：——

  公开号：——

  公开（公告）日：——